The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to ...

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In ...

Important regulatory news last week included French pharma major Sanofi gaining approval from the US Food and Drug ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The US Food and Drug Administration has approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic ...

The label expansion provides a new option for the hundreds of thousands of Americans with inadequately controlled COPD.

The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.